Abbott’s COMPARE trial demonstrates that Xience V Everolimus Eluting Coronary Stent System has shown better outcomes in safety and efficacy measures compared to the Taxus Liberte Paclitaxel-Eluting Coronary Stent System (Taxus).
At one year, Xience V demonstrated a lower incidence of adverse cardiac events (MACE) compared to Taxus (6.2% Xience V vs 9.1% Taxus, p-value= 0.023) in the trial’s primary endpoint, and target vessel revascularisation (TVR).
Additionally, Xience V demonstrated a lower rate of stent thrombosis compared to Taxus (0.7% Xience V vs 2.6% Taxus, p-value=0.002, a significantly lower rate of TVR (2.4% Xience V vs 6.0% Taxus, p-value=0.0001), and a significantly lower rate of TLR (1.7% Xience V vs 4.8% Taxus, p-value=0.0002).
John Capek, executive vice president for medical devices at Abbott, said: “The COMPARE trial, which studied a real-world, complex patient population, reaffirms what we saw in SPIRIT IV earlier today and what we’ve seen throughout our SPIRIT family of trials – with Xience V showing consistent, outstanding performance compared to Taxus, whether it’s Taxus Express in SPIRIT IV or now Taxus Liberte in the investigator-initiated study COMPARE.”